The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment
Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...
Main Authors: | Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl |
---|---|
פורמט: | Article |
שפה: | English |
יצא לאור: |
BMC
2025-01-01
|
סדרה: | BMC Complementary Medicine and Therapies |
נושאים: | |
גישה מקוונת: | https://doi.org/10.1186/s12906-025-04753-w |
פריטים דומים
-
Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis
מאת: Ana Pilar Pérez-Acevedo, et al.
יצא לאור: (2020-12-01) -
Individualised computerised cognitive training (iCCT) for community-dwelling people with mild cognitive impairment (MCI): results on cognition in the 6-month intervention period of a randomised controlled trial (MCI-CCT study)
מאת: Elmar Graessel, et al.
יצא לאור: (2024-10-01) -
3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract
מאת: Anna Gościniak, et al.
יצא לאור: (2024-11-01) -
Cannabis Contaminants Limit Pharmacological Use of Cannabidiol
מאת: Zackary Montoya, et al.
יצא לאור: (2020-09-01) -
El cannabidiol y sus indicaciones en psiquiatría
מאת: Juan Fernando Muñoz Ramírez
יצא לאור: (2021-03-01)